List view / Grid view
Researchers have developed bioactive nanoparticles that restore the brain’s blood-brain barrier and clear toxic proteins, reversing Alzheimer’s symptoms in mice and offering a promising new approach to treating the disease.
A new study shows that approved drugs, pemafibrate and telmisartan, when combined, can reduce liver fat and may lower cardiovascular risk in metabolic dysfunction-associated steatotic liver disease.
A new fibre-optic method lets researchers monitor amyloid plaque buildup in living, freely moving mice – offering a minimally invasive way to track Alzheimer’s disease progression and test potential therapies.
6 October 2025 | By
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
Researchers have discovered a surface protein that helps acute myeloid leukaemia cells evade the immune system, offering potential insights to aid the development of new treatments.
Researchers have created liver organoids from hibernating Syrian hamsters, revealing how these cells survive cold storage - a discovery that could improve liver transplant success.
Researchers have discovered that targeting immune cell ageing can overcome resistance to head and neck cancer treatment.
Severe flu in pregnancy may weaken the placenta and foetal brain, allowing harmful molecules to leak in and disrupt development, a new study finds
Korean researchers have discovered that oral bacteria in the gut may contribute to Parkinson’s disease – highlighting a potential new target for treatment.
Researchers in China have discovered how glioblastoma adapts to low-oxygen conditions – revealing a new treatment strategy that combines an orphan drug with standard chemotherapy to overcome resistance.
A new study from UT Dallas and the Medical College of Wisconsin links chronic sickle cell disease pain to gut bacteria – identifying Akkermansia muciniphila as a potential target for new probiotic or microbiome-based therapies.
A new oral immunotherapy could change how peanut allergy is treated, targeting the gut to retrain the immune system and reduce the risk of life-threatening reactions. INP20’s nanoparticle technology promises a safer, more precise approach that could replace lifelong avoidance with lasting tolerance.
As cancer drugs continue to fail in translation, researchers are turning back to patient-derived xenograft (PDX) models – this time with better science. Could they be the missing link between the lab and the clinic?
A first-in-class obesity drug, presented at the European Association for the Study of Diabetes meeting in Vienna, aims to reprogramme metabolism rather than suppress appetite – offering the potential for long-lasting weight loss without regain.
A new experimental stem cell therapy shows promise in repairing brain damage after ischemic strokes – potentially allowing for the development of future treatments that extend the recovery window.
